Last reviewed · How we verify

Lupo Center for Aesthetic and General Dermatology — Portfolio Competitive Intelligence Brief

Lupo Center for Aesthetic and General Dermatology pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PrabotulinumtoxinA-Xvfs PrabotulinumtoxinA-Xvfs marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery) Dermatology / Aesthetics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ATGC Co., Ltd. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Brigitte Schürch · 1 shared drug class
  4. Carruthers Dermatology Centre · 1 shared drug class
  5. Department of Medical Services Ministry of Public Health of Thailand · 1 shared drug class
  6. Galderma R&D · 1 shared drug class
  7. Huons Co., Ltd. · 1 shared drug class
  8. Innovaderm Research Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lupo Center for Aesthetic and General Dermatology:

Cite this brief

Drug Landscape (2026). Lupo Center for Aesthetic and General Dermatology — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lupo-center-for-aesthetic-and-general-dermatology. Accessed 2026-05-17.

Related